The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Gastroesophageal Reflux Disease (GERD) Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
The global Gastroesophageal Reflux Disease (GERD) Therapeutics market size is expected to reach US$ 4286.6 million by 2029, growing at a CAGR of -1.6% from 2023 to 2029. The market is mainly driven by the significant applications of Gastroesophageal Reflux Disease (GERD) Therapeutics in various end use industries. The expanding demands from the Heartburn and Acid reflux disorders, are propelling Gastroesophageal Reflux Disease (GERD) Therapeutics market. Antacids, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Pro-kinetic agents segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Gastroesophageal Reflux Disease (GERD) Therapeutics market, driven by demand from China, the second largest economy with some signs of stabilising, the Gastroesophageal Reflux Disease (GERD) Therapeutics market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Gastroesophageal Reflux Disease (GERD) Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Gastroesophageal Reflux Disease (GERD) Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Gastroesophageal Reflux Disease (GERD) Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Gastroesophageal Reflux Disease (GERD) Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Gastroesophageal Reflux Disease (GERD) Therapeutics covered in this report include AstraZeneca, Eisai, GSK, Takeda and Johnson & Johnson, etc.
The global Gastroesophageal Reflux Disease (GERD) Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
Eisai
GSK
Takeda
Johnson & Johnson
Global Gastroesophageal Reflux Disease (GERD) Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Gastroesophageal Reflux Disease (GERD) Therapeutics market, Segment by Type:
Antacids
Pro-kinetic agents
H2 Receptor Blockers
Proton Pump Inhibitors (PPIs)
Global Gastroesophageal Reflux Disease (GERD) Therapeutics market, by Application
Heartburn
Acid reflux disorders
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Gastroesophageal Reflux Disease (GERD) Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Gastroesophageal Reflux Disease (GERD) Therapeutics market size is expected to reach US$ 4286.6 million by 2029, growing at a CAGR of -1.6% from 2023 to 2029. The market is mainly driven by the significant applications of Gastroesophageal Reflux Disease (GERD) Therapeutics in various end use industries. The expanding demands from the Heartburn and Acid reflux disorders, are propelling Gastroesophageal Reflux Disease (GERD) Therapeutics market. Antacids, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Pro-kinetic agents segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Gastroesophageal Reflux Disease (GERD) Therapeutics market, driven by demand from China, the second largest economy with some signs of stabilising, the Gastroesophageal Reflux Disease (GERD) Therapeutics market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Gastroesophageal Reflux Disease (GERD) Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Gastroesophageal Reflux Disease (GERD) Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Gastroesophageal Reflux Disease (GERD) Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Gastroesophageal Reflux Disease (GERD) Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Gastroesophageal Reflux Disease (GERD) Therapeutics covered in this report include AstraZeneca, Eisai, GSK, Takeda and Johnson & Johnson, etc.
The global Gastroesophageal Reflux Disease (GERD) Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
Eisai
GSK
Takeda
Johnson & Johnson
Global Gastroesophageal Reflux Disease (GERD) Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Gastroesophageal Reflux Disease (GERD) Therapeutics market, Segment by Type:
Antacids
Pro-kinetic agents
H2 Receptor Blockers
Proton Pump Inhibitors (PPIs)
Global Gastroesophageal Reflux Disease (GERD) Therapeutics market, by Application
Heartburn
Acid reflux disorders
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Gastroesophageal Reflux Disease (GERD) Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Gastroesophageal Reflux Disease (GERD) Therapeutics
1.1 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Overview
1.1.1 Gastroesophageal Reflux Disease (GERD) Therapeutics Product Scope
1.1.2 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Status and Outlook
1.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Region (2018-2029)
1.4 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size (2018-2029)
1.6.1 North America Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size (2018-2029)
1.6.2 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size (2018-2029)
1.6.4 Latin America Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size (2018-2029)
2 Gastroesophageal Reflux Disease (GERD) Therapeutics Market by Type
2.1 Introduction
2.1.1 Antacids
2.1.2 Pro-kinetic agents
2.1.3 H2 Receptor Blockers
2.1.4 Proton Pump Inhibitors (PPIs)
2.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Breakdown by Type (2018-2029)
3 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Heartburn
3.1.2 Acid reflux disorders
3.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Breakdown by Application (2018-2029)
4 Gastroesophageal Reflux Disease (GERD) Therapeutics Competition Analysis by Players
4.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Gastroesophageal Reflux Disease (GERD) Therapeutics as of 2022)
4.3 Date of Key Players Enter into Gastroesophageal Reflux Disease (GERD) Therapeutics Market
4.4 Global Top Players Gastroesophageal Reflux Disease (GERD) Therapeutics Headquarters and Area Served
4.5 Key Players Gastroesophageal Reflux Disease (GERD) Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 AstraZeneca
5.1.1 AstraZeneca Profile
5.1.2 AstraZeneca Main Business
5.1.3 AstraZeneca Gastroesophageal Reflux Disease (GERD) Therapeutics Products, Services and Solutions
5.1.4 AstraZeneca Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 AstraZeneca Recent Developments
5.2 Eisai
5.2.1 Eisai Profile
5.2.2 Eisai Main Business
5.2.3 Eisai Gastroesophageal Reflux Disease (GERD) Therapeutics Products, Services and Solutions
5.2.4 Eisai Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Eisai Recent Developments
5.3 GSK
5.3.1 GSK Profile
5.3.2 GSK Main Business
5.3.3 GSK Gastroesophageal Reflux Disease (GERD) Therapeutics Products, Services and Solutions
5.3.4 GSK Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Takeda Recent Developments
5.4 Takeda
5.4.1 Takeda Profile
5.4.2 Takeda Main Business
5.4.3 Takeda Gastroesophageal Reflux Disease (GERD) Therapeutics Products, Services and Solutions
5.4.4 Takeda Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Takeda Recent Developments
5.5 Johnson & Johnson
5.5.1 Johnson & Johnson Profile
5.5.2 Johnson & Johnson Main Business
5.5.3 Johnson & Johnson Gastroesophageal Reflux Disease (GERD) Therapeutics Products, Services and Solutions
5.5.4 Johnson & Johnson Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Johnson & Johnson Recent Developments
6 North America
6.1 North America Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Dynamics
11.1 Gastroesophageal Reflux Disease (GERD) Therapeutics Industry Trends
11.2 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Drivers
11.3 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Challenges
11.4 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
